Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atuliflapon in moderate to severe uncontrolled asthma
NCT05251259Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of atuliflapon in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Time to first Composite Endpoint for Exacerbations Asthma event at 12 weeks. Started Jan 2022; status: completed.
02
Drugs
atuliflapon
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05251259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251259.